following an abbreviated submission:
abatacept (Orencia®) powder for solution for injection is accepted for restricted use within NHS Scotland.
Indication under review: in combination with methotrexate, abatacept is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other disease modifying antirheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor. It has not been studied in children under 6 years old.
It should be restricted to use within specialist rheumatology services (including those working within the network for paediatric rheumatology). Abatacept is an anti-rheumatic agent that prevents T-lymphocyte activation.
Abatacept in combination with methotrexate has been accepted for restricted use in adults with severe active rheumatoid arthritis in line with the recommendations of the NICE Multiple Technology Appraisal no 195. NHS Quality Improvement Scotland advised that these recommendations were valid for NHS Scotland.
Download detailed advice80KB (PDF)
Medicine details
- Medicine name:
- abatacept (Orencia)
- SMC ID:
- 618/10
- Indication:
- In combination with methotrexate, abatacept is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other disease modifying antirheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor. It has not been studied in children under 6 years old.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Superseded
- Date advice published
- 07 November 2011